Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Vaginal Intraepithelial Neoplasia

High-Risk HPV in VaIN: Can Testing Date the Infection?

At a Glance

A high-risk HPV result in vaginal intraepithelial neoplasia (VaIN) indicates a type linked to abnormal cells, but it does not by itself diagnose invasive cancer. HPV testing cannot show when the infection began or who transmitted it; biopsy grade and clinical history guide follow-up.

Learning that you have a high-risk human papillomavirus (HPV) infection can be frightening, especially if it raises concerns about cancer or relationship fidelity. It is important to know that HPV is incredibly common, and a positive result is not a judgment about your behavior.

If your vaginal biopsy shows HPV-related Vaginal Intraepithelial Neoplasia (VaIN), a high-risk HPV test means that a strain of HPV associated with abnormal cell changes is present in your vaginal cells [1]. Leukoplakia is a medical term for a visible white patch on the vaginal wall; it is a descriptive finding, not a diagnosis, and can have non-HPV causes [2]. A biopsy is required to confirm whether the white patch is VaIN. While the HPV is likely contributing to the abnormal cells, an HPV test cannot determine when you acquired the virus, how long you have had it, or who transmitted it [3][4].

What is VaIN, and What Does High-Risk HPV Mean?

VaIN refers to abnormal cells in the surface lining of the vagina. It is not invasive cancer. High-risk HPV is strongly associated with these cellular changes, but an HPV result should be interpreted carefully:

  • It is a risk marker, not a cancer diagnosis: High-risk HPV is commonly found in high-grade VaIN (VaIN 2 or 3) [5][6]. While high-grade VaIN has the potential to progress to invasive vaginal cancer, a positive HPV result alone does not mean you have cancer [7][8].
  • Genotype matters: A genotype is a specific strain of the virus. Certain strains, particularly HPV16, carry a higher risk of causing high-grade VaIN and are more strongly linked to disease persistence and progression [5][7].
  • It can guide your follow-up care: While HPV tests are primarily designed and validated for cervical screening, they are sometimes used for vaginal specimens. Persistent high-risk HPV after treatment is a strong predictor of VaIN returning (recurrence) [9][10]. Because of this, some doctors use HPV testing alongside clinical exams and pathology to determine how closely to monitor you [11].

Why HPV Testing Cannot Date Your Infection

It is natural to wonder when you caught HPV, particularly if you are in a long-term monogamous relationship. However, no medical test can timeline an HPV infection or prove recent sexual transmission, due to how the virus behaves [3][4]:

  • Latency and Reactivation: HPV can remain dormant (latent) in your body’s cells for years or even decades without causing symptoms or shedding enough virus to be detected by a test [12][4]. A positive result often means an older infection has reactivated.
  • Fluctuating Detectability: The virus can transition in and out of detectability. A negative HPV test does not guarantee the virus has been completely eradicated; it only means the amount of virus was below the detection threshold at the time of the swab [12][13].
  • Transmission is untraceable: Even if both partners test positive for the exact same HPV genotype, medical science cannot determine who originally transmitted it to whom [4].

To highlight this, one study of women aged 35 to 60 found that only a minority (19.4%) of new HPV detections were linked to a new sexual partner. The majority were interpreted as reactivations of previously acquired infections [3]. A positive HPV result is not evidence that a partner has recently been unfaithful.

Understanding Persistence and Clearance

Your immune system continuously interacts with the HPV virus. “Persistent” infections are those that remain detectable over multiple tests, and these are the most likely to cause cellular changes like VaIN [14][10].

While many infections become undetectable over time, the timeline varies widely. In a large meta-analysis of over 600,000 participants with HPV, researchers found that about half of infections defined as “persistent” eventually became undetectable on testing within two years [14]. It is important to note that this is a broad population statistic, not a personal prediction for your VaIN, and becoming “undetectable” means the virus is suppressed, not necessarily completely cleared from the body [12]. Host factors, such as your immune system health and whether you smoke, can influence how long the virus remains active [15][16].

What to Expect Next

Your care team will not base your treatment on the HPV result alone. Management depends on your specific biopsy results and clinical history:

  • Reviewing Pathology: Your doctor will look at the exact grade of your VaIN (such as VaIN 1, 2, or 3) and confirm that invasive cancer has been ruled out.
  • Treatment vs. Observation: Lower-grade changes (VaIN 1) might just be observed, while high-grade changes (VaIN 2 or 3) are typically treated to prevent progression [11].
  • Vaccination: You may discuss whether you are a candidate for the HPV vaccine. While the vaccine does not treat an existing infection or existing VaIN, it can protect against other strains you have not been exposed to.

When to Contact Your Clinician

While VaIN itself often has no symptoms, it is important to report any concerning changes to your care team. Call your doctor if you experience:

  • New or unexplained vaginal bleeding, especially after sex or after menopause
  • Watery or bloody vaginal discharge
  • Increasing pelvic pain
  • A new or changing visible mass in the vagina

While these symptoms do not automatically mean you have cancer, they warrant a prompt clinical evaluation [17][18].

Common questions in this guide

What does a high-risk HPV result mean if I have VaIN?
It means a type of HPV linked to abnormal cell changes was found in vaginal cells. It is a risk marker and does not by itself mean you have invasive cancer; the VaIN grade and biopsy findings are important for understanding your care.
Can an HPV test tell when I caught the infection?
No. HPV can stay quiet for years, become detectable again, or fall below the test’s detection limit, so testing cannot show when the infection began, how long it has been present, or who transmitted it.
Does a positive HPV test prove recent infidelity?
No. HPV is common and can remain latent before reactivating, so a new positive result does not prove a recent sexual exposure or tell which partner transmitted it.
Is HPV16 more concerning in VaIN?
HPV16 is more strongly associated with high-grade VaIN, persistence, and progression than some other HPV types. Your clinician will interpret the genotype together with your biopsy results and clinical history rather than using it alone.
What happens after high-risk HPV is found with VaIN?
Your follow-up depends on the VaIN grade, biopsy findings, and medical history. Lower-grade VaIN may be observed, while high-grade VaIN is typically treated; follow-up may include vaginal examinations, Pap testing, or repeat HPV testing.
Can the HPV vaccine treat my existing VaIN or HPV infection?
The HPV vaccine does not treat an existing HPV infection or VaIN. It may protect against HPV types you have not encountered, so ask your clinician whether vaccination is appropriate for you.
What symptoms should I report with VaIN?
Report new unexplained vaginal bleeding, especially after sex or menopause, watery or bloody discharge, increasing pelvic pain, or a new or changing vaginal mass. These symptoms do not automatically mean cancer, but they should be evaluated promptly.

Get notified when new evidence is published on leukoplakia of vagina.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Detection of high-risk human papillomavirus infection and treatment of high-grade vaginal intraepithelial neoplasia: A single-institution study.

    Cho HW, Hong JH, Lee JK

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021; (154(2)):227-232 doi:10.1002/ijgo.13583.

    PMID: 33411347
  2. 2

    First Reported Case of Invasive Cervical Squamous Cell Carcinoma Arising From an HPV 42-associated Seborrhoeic Keratosis-like Lesion of the Cervix and Vagina.

    Gardner K, Bryson G, Smith D, et al.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2026; doi:10.1097/PGP.0000000000001170.

    PMID: 41875374
  3. 3

    Rates of New Human Papillomavirus Detection and Loss of Detection in Middle-aged Women by Recent and Past Sexual Behavior.

    Paul P, Hammer A, Rositch AF, et al.

    The Journal of infectious diseases 2021; (223(8)):1423-1432 doi:10.1093/infdis/jiaa557.

    PMID: 32870982
  4. 4

    HPV Infections in Heterosexual Couples: Mechanisms and Covariates of Virus Transmission.

    Kero K, Rautava J

    Acta cytologica 2019; (63(2)):143-147 doi:10.1159/000494710.

    PMID: 30799413
  5. 5

    A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients.

    Ao M, Zheng D, Wang J, et al.

    Journal of medical virology 2022; (94(2)):737-744 doi:10.1002/jmv.27311.

    PMID: 34460120
  6. 6

    Characteristics of high-risk HPV infection in women with vaginal intraepithelial neoplasia in Beijing, China.

    Ye Y, Li M, Yang W, et al.

    Journal of medical virology 2023; (95(12)):e29267 doi:10.1002/jmv.29267.

    PMID: 38082564
  7. 7

    Human Papillomavirus Genotype Attribution and Integration in High-Grade Vaginal Intraepithelial Neoplasia.

    Shen Y, Tang S, Zhou Y, et al.

    Journal of lower genital tract disease 2025; (29(1)):60-67 doi:10.1097/LGT.0000000000000850.

    PMID: 39620892
  8. 8

    High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).

    Sopracordevole F, Barbero M, Clemente N, et al.

    European review for medical and pharmacological sciences 2016; (20(5)):818-24.

    PMID: 27010135
  9. 9

    LASER treatment for women with high-grade vaginal intraepithelial neoplasia: A propensity-matched analysis on the efficacy of ablative versus excisional procedures.

    Bogani G, Ditto A, Martinelli F, et al.

    Lasers in surgery and medicine 2018; (50(9)):933-939 doi:10.1002/lsm.22941.

    PMID: 29756652
  10. 10

    Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia.

    Bogani G, Martinelli F, Ditto A, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2017; (210()):157-165 doi:10.1016/j.ejogrb.2016.12.020.

    PMID: 28039759
  11. 11

    The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia.

    Kesic V, Carcopino X, Preti M, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(4)):446-461 doi:10.1136/ijgc-2022-004213.

    PMID: 36958755
  12. 12

    Natural History of HPV Infection across the Lifespan: Role of Viral Latency.

    Gravitt PE, Winer RL

    Viruses 2017; (9(10)) doi:10.3390/v9100267.

    PMID: 28934151
  13. 13

    Clearance and persistence of the human papillomavirus infection among Cameroonian women.

    Akaaboune M, Kenfack B, Viviano M, et al.

    Women's health (London, England) 2018; (14()):1745506518805642 doi:10.1177/1745506518805642.

    PMID: 30353785
  14. 14

    Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis.

    Zhao M, Kang P, Zhu L, et al.

    iScience 2024; (27(10)):110991 doi:10.1016/j.isci.2024.110991.

    PMID: 39474077
  15. 15

    Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women.

    Yunihastuti E, Teeratakulpisarn N, Jeo WS, et al.

    AIDS (London, England) 2020; (34(13)):1933-1941 doi:10.1097/QAD.0000000000002654.

    PMID: 32773478
  16. 16

    Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.

    Stensen S, Kjaer SK, Jensen SM, et al.

    International journal of cancer 2016; (138(2)):361-8 doi:10.1002/ijc.29719.

    PMID: 26238558
  17. 17

    Individualized vaginal applicator for stage IIb primary vaginal adenocarcinoma: A case report.

    Saijilafu , Gu YJ, Huang AW, et al.

    World journal of clinical oncology 2024; (15(8)):1102-1109 doi:10.5306/wjco.v15.i8.1102.

    PMID: 39193155
  18. 18

    Vaginal epithelioid angiosarcoma: A literature review of a rare entity in an unusual site.

    Weishaupt J, Miller J, Oehler MK

    Gynecologic oncology reports 2021; (36()):100706 doi:10.1016/j.gore.2021.100706.

    PMID: 33604443

This page is for informational purposes only and does not constitute medical advice. Ask your clinician to interpret your VaIN grade, HPV results, symptoms, and follow-up plan.